查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552620

螢光原位雜合反應成像系統市場規模、佔有率、趨勢分析報告：按產品、應用、最終用途、地區和細分市場預測，2024-2030 年

Fluorescence In Situ Hybridization Imaging Systems Market Size, Share & Trends Analysis Report By Product (Instruments), By Application (Cancer Diagnosis), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

螢光原位雜合反應成像系統市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球螢光雜合反應成像系統市場規模將達21.4億美元，2024年至2030年複合年成長率為8.4%。

與體外診斷相關的研發投資的增加預計將推動螢光原位雜合反應（FISH）成像系統市場的發展。歐洲診斷製造商協會等政府機構的存在也對成長做出了貢獻，該協會專注於開拓和發展歐洲體外診斷市場。

此外，FISH 成像系統在診斷領域越來越受歡迎，以確定疑似由病原體和細菌引起的疾病。淋巴瘤、固態腫瘤、白血病、自閉症和其他發育綜合症等遺傳性疾病發病率的增加預計也將推動採用。螢光檢查設備、顯微鏡、照明器和 CCD 相機在傳染病檢查中變得越來越常見，這些系統的成長機會正在擴大。預計該市場將受到與染色體異常相關的疾病（例如癌症和遺傳異常）日益流行以及開發中國家未滿足的診斷和臨床需求的推動。

此外，對快速、靈敏和準確的疾病檢驗診斷技術的需求不斷增加，意識不斷提高，醫療保健支出不斷增加，以及開發新型成像系統的廣泛研究和開發也將推動預測期內的成長。

螢光雜合反應成像系統市場報告亮點

  • FISH 成像服務預計在預測期內將以最快的速度成長。
  • 目前，FISH成像在癌症診斷的市場滲透率非常高，因此診斷實驗室部門佔了較大的收益。
  • 由於癌症發生率不斷上升，癌症診斷佔據了最大的收益佔有率，刺激了 FISH 影像系統的採用。
  • 在最終用途領域，伴同性診斷預計將比研究和診斷成長更快。
  • 這些系統主要用於各種臨床研究，包括子宮頸癌癌前病變的可視化、人類乳突病毒風險評估、白血病、骨髓發育不良症候群、多發性骨髓瘤和染色體異常的檢測，因此診斷實驗室佔據了主導地位。
  • 由於這些解決方案在該地區的研發中廣泛採用，北美地區佔據了最大的收益佔有率。
  • 由於製造商和政府的投資增加、政府在生物技術領域的積極舉措以及大量開拓機會的存在，預計亞太地區在預測期內將呈現良好的複合年成長率。
  • 該行業競爭激烈，少數玩家佔了整體收益的大部分。一些最著名的市場參與企業包括 Euroclone SpA、TissueGnostics GmbH、安捷倫科技公司、Abnova 台灣公司、BioGenex Laboratories Inc.、o Bio-View Ltd. 和通用電氣公司。這些在該行業中佔據了很大的佔有率。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章螢光原位雜合反應成像系統的變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 螢光原位雜合反應成像系統分析工具
    • 波特的分析
    • PESTEL分析

第4章螢光雜合反應成像系統市場：依產品估計和趨勢分析

  • 細分儀表板
  • 螢光原位雜合反應成像系統市場：2023 年和 2030 年產品變化分析
  • 裝置
  • 耗材及配件
  • 服務
  • 軟體

第5章螢光雜合反應成像系統：應用估計與趨勢分析

  • 細分儀表板
  • 螢光原位雜合反應成像系統市場：2023 年和 2030 年應用變化分析
  • 癌症診斷
    • 2018-2030 年市場收益估計與預測
    • 肺癌
    • 乳癌
    • 其他
  • 遺傳性疾病的診斷
    • 2018-2030 年市場收益估計與預測
  • 其他
    • 2018-2030 年市場收益估計與預測

第 6 章螢光原位雜合反應成像系統：依最終用途進行估算與趨勢分析

  • 細分儀表板
  • 螢光原位雜合反應成像系統市場：2023 年和 2030 年最終用途變化分析
  • 診斷實驗室
    • 2018-2030 年市場收益估計與預測
  • 研究/學術機構
    • 2018-2030 年市場收益估計與預測
  • 其他
    • 2018-2030 年市場收益估計與預測

第7章螢光雜合反應成像系統市場：區域估計與趨勢分析

  • 2023 年和 2030 年螢光原位雜合反應成像系統按地區佔有率
  • 北美洲
    • 北美螢光原位雜合反應影像系統估算與預測，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年歐洲螢光原位雜合反應成像系統的估算與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030年亞太地區螢光原位雜合反應成像系統的估算與預測
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲螢光原位雜合反應成像系統的估計和預測，2018-2030
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2018-2030 年中東和非洲螢光雜合反應成像系統的估算和預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Euroclone SpA
    • TissueGnostics GmbH
    • Agilent Technologies, Inc.
    • Abnova Taiwan Corp
    • BioGenex Laboratories Inc
    • Leica Biosystems Nussloch GmbH
    • Bio-View Ltd
    • Thermo Fisher Scientific, Inc.
    • MetaSystems Probes GmbH
簡介目錄
Product Code: GVR-1-68038-653-0

Fluorescence In Situ Hybridization Imaging Systems Market Growth & Trends:

The global fluorescence in situ hybridization imaging systems market size is expected to reach USD 2.14 billion by 2030, expanding at a CAGR of 8.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D investments pertaining to in vitro diagnostics are expected to drive the Fluorescence In Situ Hybridization (FISH) imaging systems market. The presence of government organizations, such as the European Diagnostic Manufacturers Association that focuses on the development and growth of the in vitro diagnostics market in Europe, is also contributing to growth.

Furthermore, FISH imaging systems are gaining popularity in diagnostics for the determination of suspected diseases caused by pathogens or bacteria. Increasing incidence of genetic diseases, such as lymphoma, solid tumors, leukemia, autism, and other developmental syndromes, is also expected to boost adoption. Growing penetration of fluoroscopy, microscopes, illuminators, and CCD cameras in testing for infectious diseases is expanding growth opportunities for these systems. Increasing prevalence of diseases with chromosomal aberrations, such as cancer and genetic abnormalities, as well as unmet diagnostic & clinical needs in developing countries, is anticipated to drive the market.

Moreover, increasing demand for rapid, sensitive, & accurate diagnostic techniques for validation of diseases, coupled with rising awareness, increase in healthcare expenditure, and extensive R&D for the development of novel imaging systems are also expected to drive growth over the forecast period.

Fluorescence In Situ Hybridization Imaging Systems Market Report Highlights:

  • Instruments held the largest market, whereas FISH imaging services are expected to grow at the fastest rate during the forecast period
  • At present, the market penetration of FISH imaging in cancer diagnostics is very high, hence the diagnostic laboratories segment accounted for larger revenues
  • Cancer diagnosis held the largest revenue share owing to increasing incidence of cancer, thus fueling the adoption of FISH imaging systems
  • Among end-use segments, companion diagnostics is expected to witness faster growth than research and diagnostic segments
  • Diagnostic laboratories held the dominant position in 2016 as these systems are predominantly used in various clinical studies for visualization of precancerous lesions in cervical cancer, assessing the risk of human papillomavirus, and for detection of leukemia, myelodysplastic syndrome, multiple myeloma, & chromosomal abnormalities
  • North America held the largest revenue share owing to extensive adoption of these solutions in research and development across this region
  • Asia Pacific is anticipated to exhibit lucrative CAGR over the forecast period due to the increase in investments by manufacturers & governments, supportive government initiatives in the biotechnology sector, and the presence of a large number of untapped opportunities
  • The industry is highly competitive with a limited number of players holding a majority of the overall revenues. Some of the most notable market participants are Euroclone SpA, TissueGnostics GmbH, Agilent Technologies, Inc., Abnova Taiwan Corp, BioGenex Laboratories Inc., o Bio-View Ltd and General Electric Company. They account for a considerable share of the industry

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Fluorescence In Situ Hybridization Imaging Systems Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Fluorescence In Situ Hybridization Imaging Systems Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Fluorescence In Situ Hybridization Imaging Systems Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Fluorescence In Situ Hybridization Imaging Systems Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Instruments
    • 4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Microscopes
      • 4.3.2.1. Microscopes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Automated cell analyzers
      • 4.3.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Others
      • 4.3.4.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Consumables & Accessories
    • 4.4.1. Consumables & Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Software
    • 4.6.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Fluorescence In Situ Hybridization Imaging Systems: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Fluorescence In Situ Hybridization Imaging Systems Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Cancer Diagnosis
    • 5.3.1. Cancer Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Lung Cancer
      • 5.3.2.1. Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Breast Cancer
      • 5.3.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Genetic Disease Diagnosis
    • 5.4.1. Genetic Disease Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Fluorescence In Situ Hybridization Imaging Systems: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Fluorescence In Situ Hybridization Imaging Systems Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Research & Academic Institutes
    • 6.4.1. Research & Academic Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Fluorescence In Situ Hybridization Imaging Systems Market: Regional Estimates & Trend Analysis

  • 7.1. Fluorescence In Situ Hybridization Imaging Systems Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Sweden Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Fluorescence In Situ Hybridization Imaging Systems and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Euroclone SpA
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. TissueGnostics GmbH
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Agilent Technologies, Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Abnova Taiwan Corp
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. BioGenex Laboratories Inc
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Leica Biosystems Nussloch GmbH
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bio-View Ltd
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Thermo Fisher Scientific, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. MetaSystems Probes GmbH
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives